Immunomedics, Inc. (Nasdaq: IMMU) today announced that naked veltuzumab enhances the therapeutic response to a veltuzumab-based pretargeted radioimmunotherapy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE